Tibsovo (ivosidenib) / Servier, CStone Pharma, Schrodinger  >>  Phase 1
Welcome,         Profile    Billing    Logout  

13 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tibsovo (ivosidenib) / Servier
NCT05756777: A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Recruiting
1b
36
US
Gilteritinib, Ivosidenib, Enasidenib
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc.
Acute Myeloid Leukemia (AML)
02/25
02/25
AG120-221-C-001, NCT02632708: Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Checkmark Updated data from P1 trial in combination with chemotherapy in IDH1/2m newly diagnosed AML at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: Updated data from P1 trial in combination with chemotherapy in IDH1/2m newly diagnosed AML at ASH 2018 [screenshot]
Checkmark First data in combination trial of enasidenib or ivosidenib with standard of care intensive chemotherapy at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: First data in combination trial of enasidenib or ivosidenib with standard of care intensive chemotherapy at ASH 2017 [screenshot]
Checkmark Initiation of P1b combination trials for frontline AML
More
Active, not recruiting
1
153
Europe, US
AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide
Institut de Recherches Internationales Servier, Celgene Corporation
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
12/18
07/24
NCT03343197: Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Checkmark From perioperative 'window' trial in combination with vorasidenib for low grade glioma at ASCO 2019
Jun 2019 - Jun 2019: From perioperative 'window' trial in combination with vorasidenib for low grade glioma at ASCO 2019
Active, not recruiting
1
49
US
AG-120, AG881
Institut de Recherches Internationales Servier
Glioma
08/19
05/25
NCT04176393: A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

Checkmark Data from a China registrational bridging study for r/r AML at ESMO 2021
Sep 2021 - Sep 2021: Data from a China registrational bridging study for r/r AML at ESMO 2021
Checkmark Data from trial for Chinese patients with r/r AML
Aug 2021 - Aug 2021: Data from trial for Chinese patients with r/r AML
Completed
1
30
RoW
ivosidenib, TIBSOVO
CStone Pharmaceuticals
Relapsed or Refractory Acute Myeloid Leukemia
02/21
01/23
NCT03564821: IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Completed
1
18
US
Ivosidenib
Massachusetts General Hospital, Agios Pharmaceuticals, Inc.
IDH1 Mutation Myeloid Neoplasms
05/22
06/23
NCT05209074: Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Recruiting
1
16
US
Ivosidenib, mFOLFIRINOX
Case Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
10/24
10/24
NCT02073994: Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Checkmark From P1 study of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: From P1 study of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies at ASCO 2018 [screenshot]
Checkmark From study for recurrent or progressive IDH1 mutant glioma at SNO 2017 [screenshot]
Nov 2017 - Nov 2017: From study for recurrent or progressive IDH1 mutant glioma at SNO 2017 [screenshot]
Checkmark PK/PD data in IDH1-mutant cholangiocarcinoma at ASCO 2017
More
Completed
1
174
Europe, US
AG-120
Institut de Recherches Internationales Servier
Cholangiocarcinoma, Chondrosarcoma, Glioma, Other Advanced Solid Tumors
01/24
01/24
NCT06291987: Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Not yet recruiting
1
18
US
Ivosidenib, TIBSOVO, Ruxolitinib, Jakafi
University of Chicago
Myeloproliferative Neoplasms
05/26
05/26
NCT04088188: Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Terminated
1
8
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Ivosidenib, AG-120, Tibsovo, Pemigatinib, INCB054828, Pemazyre
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma
12/23
12/23
AG120-C-001, NCT02074839: Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Checkmark Updated data from trial in patients with IDH1-mutant untreated AML at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: Updated data from trial in patients with IDH1-mutant untreated AML at ASCO 2019 [screenshot]
Checkmark From trial in patients with IDH1-mutant untreated AML at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: From trial in patients with IDH1-mutant untreated AML at ASH 2018 [screenshot]
Checkmark From trial for MDS at ASH 2018 [screenshot]
More
Recruiting
1
291
Europe, US
AG-120
Institut de Recherches Internationales Servier
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
02/25
08/25
NCT04955938: A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Recruiting
1
50
US
Ivosidenib, Tibsovo, Enasidenib, IDHIFA, Fedratinib, INREBIC
University of Chicago
IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation, Blood Cancer, Myeloproliferative Neoplasm
10/25
10/25
NCT04250051: Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1
25
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Fludarabine, Fluradosa, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Ivosidenib, AG-120, Tibsovo
Northwestern University, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
12/26
12/28
NCI-2021-08496, NCT05010772: Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Recruiting
1
125
US
Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Enasidenib, AG-221, CC-90007 Free Base, Gilteritinib, ASP-2215, ASP2215, Ivosidenib, AG-120, Tibsovo, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia
12/26
12/26

Download Options